Stock Events

Stock Events

Agenus 

€3.34
222
-€0.02-0.6% Monday 06:03

Statistics

Day High
3.34
Day Low
3.34
52W High
5.85
52W Low
2.38
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q4 2025
Next
-0.91
-0.01
0.89
1.79
Expected EPS
1.792119
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AJ8.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap277.02B
Merck & Co. is a leading pharmaceutical company that competes with Agenus in the immuno-oncology space, particularly with its blockbuster cancer drug, Keytruda, which directly competes with Agenus' cancer immunotherapies.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb is a major player in the development of immunotherapies for cancer, competing with Agenus in the development of novel treatments for various cancers through its extensive portfolio of immune checkpoint inhibitors.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences competes with Agenus in the oncology and immuno-oncology fields, particularly through its acquisition of Kite Pharma, which has expanded its presence in cancer immunotherapy.
Novartis
NVS
Mkt Cap279.67B
Novartis competes with Agenus in the cancer treatment space, especially in the development of CAR-T cell therapies and other innovative immunotherapies for cancer.
Pfizer
PFE
Mkt Cap149.77B
Pfizer competes across a broad range of therapeutic areas including oncology, where its development of cancer immunotherapies and vaccines puts it in direct competition with Agenus.
Roche
RHHBY
Mkt Cap328.49B
Roche, through its Genentech division, is a leading company in cancer immunotherapy, competing with Agenus in the development of monoclonal antibodies and other innovative treatments for cancer.
AMGEN
AMGN
Mkt Cap178B
Amgen competes with Agenus in the oncology sector, particularly in the development of cancer immunotherapies and targeted treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals is known for its innovative treatments in oncology, competing with Agenus in the development of cancer immunotherapies, including checkpoint inhibitors.
Incyte
INCY
Mkt Cap19.36B
Incyte Corporation competes with Agenus in the field of immuno-oncology, focusing on the development of novel immunotherapies for cancer, including checkpoint inhibitors.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca competes with Agenus in the oncology space, particularly in the development and commercialization of cancer immunotherapies, making it a direct competitor in the immuno-oncology market.

About

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Show more...
CEO
Dr. Garo H. Armen Ph.D.
Employees
81
Country
United States
ISIN
US00847G8042

Listings

MU
DE
AJ8.MU
BOATS
BOATS
AGEN.BOATS
F
DE
AJ8.F
XNAS
US
AGEN

0 Comments

Share your thoughts

FAQ

What is Agenus stock price today?▼
The current price of AJ8.MU is €3.34 EUR — it has decreased by -0.6% in the past 24 hours. Watch Agenus stock price performance more closely on the chart.
What is Agenus stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Agenus stocks are traded under the ticker AJ8.MU.
Is Agenus stock price growing?▼
AJ8.MU stock has fallen by -3.47% compared to the previous week, the month change is a +14.38% rise, over the last year Agenus has showed a +28.46% increase.
When is the next Agenus earnings date?▼
Agenus is going to release the next earnings report on May 12, 2026.
What were Agenus earnings last quarter?▼
AJ8.MU earnings for the last quarter are -0.26 EUR per share, whereas the estimation was -0.91 EUR resulting in a +71.25% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Agenus have?▼
As of May 06, 2026, the company has 81 employees.
In which sector is Agenus located?▼
Agenus operates in the Other sector.
When did Agenus complete a stock split?▼
Agenus has not had any recent stock splits.
Where is Agenus headquartered?▼
Agenus is headquartered in Lexington, United States.